Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Boosts Stake in Nektar Therapeutics $NKTR

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. boosted its stake in shares of Nektar Therapeutics (NASDAQ:NKTR) by 22.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 188,112 shares of the biopharmaceutical company’s stock after buying an additional 34,266 shares during the period. Nektar Therapeutics accounts for about 0.7% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s investment portfolio, making the stock its 27th biggest holding. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned approximately 0.92% of Nektar Therapeutics worth $7,953,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of NKTR. Deutsche Bank AG lifted its holdings in shares of Nektar Therapeutics by 0.8% during the 4th quarter. Deutsche Bank AG now owns 90,743 shares of the biopharmaceutical company’s stock valued at $3,837,000 after purchasing an additional 743 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Nektar Therapeutics during the 4th quarter valued at $1,121,000. Erste Asset Management GmbH lifted its holdings in shares of Nektar Therapeutics by 64.7% during the 4th quarter. Erste Asset Management GmbH now owns 28,000 shares of the biopharmaceutical company’s stock valued at $1,196,000 after purchasing an additional 11,000 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Nektar Therapeutics by 793,605.3% during the 4th quarter. JPMorgan Chase & Co. now owns 150,804 shares of the biopharmaceutical company’s stock valued at $6,376,000 after purchasing an additional 150,785 shares during the last quarter. Finally, ING Groep NV purchased a new stake in shares of Nektar Therapeutics during the 4th quarter valued at $4,228,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Wall Street Analyst Weigh In

NKTR has been the subject of several analyst reports. Piper Sandler increased their price objective on Nektar Therapeutics from $105.00 to $192.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Citigroup increased their price objective on Nektar Therapeutics from $123.00 to $151.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. TD Cowen started coverage on Nektar Therapeutics in a report on Tuesday, March 17th. They set a “buy” rating for the company. HC Wainwright lifted their price objective on shares of Nektar Therapeutics from $165.00 to $185.00 and gave the stock a “buy” rating in a research note on Monday, April 20th. Finally, Oppenheimer reiterated an “outperform” rating and set a $140.00 price objective on shares of Nektar Therapeutics in a research note on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Nektar Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $149.63.

Nektar Therapeutics Price Performance

NASDAQ NKTR opened at $56.78 on Thursday. The stock’s fifty day moving average price is $75.18 and its 200 day moving average price is $62.20. Nektar Therapeutics has a 1 year low of $7.99 and a 1 year high of $109.00. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -6.74 and a beta of 1.13.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.58) by ($0.24). The firm had revenue of $10.86 million during the quarter, compared to analyst estimates of $10.69 million. Nektar Therapeutics had a negative net margin of 284.18% and a negative return on equity of 85.40%. Research analysts expect that Nektar Therapeutics will post -9.45 earnings per share for the current year.

Insiders Place Their Bets

In other Nektar Therapeutics news, CEO Howard W. Robin sold 444 shares of the stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $65.51, for a total transaction of $29,086.44. Following the sale, the chief executive officer directly owned 75,045 shares of the company’s stock, valued at approximately $4,916,197.95. This trade represents a 0.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.50% of the company’s stock.

Nektar Therapeutics Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.